MK-767. Kyorin/Banyu/Merck.
暂无分享,去创建一个
MK-767 (KRP-297, L-410198) is a peroxisome proliferator-activated receptor (PPAR) alpha and PPAR gamma agonist under development by Banyu, Kyorin and Merck for the potential treatment of diabetes. The compound is currently undergoing phase III trials in the US and phase I trials in Japan.